Irisin Predicts Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide DOI Creative Commons
Tetiana A. Berezina,

Oleksandr O. Berezin,

Ye. V. Novikov

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(12), P. 1615 - 1615

Published: Dec. 17, 2024

Background: Despite existing evidence of the high predictive value natriuretic peptides (NPs) in patients with heart failure (HF), treated guideline-directed therapy who have low or near-normal NP levels are unlikely to be correctly stratified for risk clinical outcomes. The aim this study is detect plausible predictors poor one-year outcomes HFpEF and NT-proBNP accordance conventional guidelines. Methods: A total 337 HF preserved ejection fraction (HFpEF) had N-terminal pro-peptide (NT-proBNP) at discharge due optimal guideline-based were enrolled study. course observation was 3 years. Echocardiography assessment hematological biochemical parameters, including NT-proBNP, tumor necrosis factor-alpha, high-sensitivity C-reactive protein (hs-CRP), adropin, irisin, visfatin, fetuin-A, performed baseline end Results: Three-year cumulative endpoints (cardiovascular death, myocardial infarction unstable angina acute coronary syndrome, worsening HF, sudden cardiac cardiac-related surgery all-cause death) detected 104 patients, whereas 233 did not meet endpoint. After adjusting an age ≥ 64 years a presence atrial fibrillation, diabetes mellitus, chronic kidney disease (CKD) stages 1–3 dilated cardiomyopathy, multivariable Cox regression analysis showed that irisin level ≤7.2 ng/mL independent predictor Moreover, > 7.2 better Kaplan–Meier survival rate than those lower serum (≤7.2 ng/mL). Conclusions: Multivariable years; CKD cardiomyopathy; LAVI 39 mL/m2; hs-CRP 6.10 mg/L, ≤ ng/mL, visfatin 1.1 NT-proBNP. could emerge as valuable biomarker predicting long-term prognosis among

Language: Английский

Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy DOI Open Access

Sheethal G Oommen,

Ruzhual K Man,

Keerthi Talluri

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: June 6, 2024

Recently, a new category of heart failure with improved ejection fraction (HFimpEF) has emerged in the classification system. This is defined as subgroup patients reduced (HFrEF) whose left ventricular recovered partially or completely, no specific cut-off values established yet guidelines. In our review, we aim to provide an overview prevalence, predictors, mechanism remodeling, and management strategies regarding HFimpEF. These constitute sizeable cohort among fraction. Certain patient characteristics including younger age female gender, absence comorbid conditions, low levels biomarkers, non-ischemic etiology were identified positive predictors. The undergoes significant maladaptive changes post leading adverse remodeling influenced duration. Goal-directed medical therapy beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) have notably cardiac function by inducing reverse remodeling. Despite more favorable prognosis compared HFrEF, (EF) still face clinical events quality life, remain at risk outcomes. Although evidence scarce, it advisable continue treatment modalities despite improvement EF, device therapies, prevent relapse deterioration. It imperative conduct further research understand EF amelioration establish guidelines identify direct strategies.

Language: Английский

Citations

5
Serum Levels of Irisin Are Positively Associated with Improved Cardiac Function in Patients with Heart Failure with Reduced Ejection Fraction DOI Creative Commons
Alexander Е. Berezin, Tetiana A. Berezina, Ye. V. Novikov

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 866 - 866

Published: April 3, 2025

Background: The purpose of the study is to investigate a possible predictive value irisin for improved left ventricular (LV) ejection fraction (EF) in discharged patients with known heart failure reduced (HFrEF). Methods: We included 313 who were HFrEF (at admission, LVEF ≤ 40%) and monitored 3 months. HF (HFimpEF) was characterized as >40% increase on transthoracic B-mode echocardiography within months follow-up. Circulating biomarkers including NT-proBNP detected at baseline after observation. By third month, 117 (37.4%) had HFimpEF, whereas 196 individuals categorized having persistent HFrEF. Results: found that HFimpEF related lower LV end-diastolic dimensions concentrations higher atrial volume index (LAVI) than those most balanced cut-offs (improved versus non-improved LVEF) 10.8 ng/mL 1540 pmol/L, respectively. Multivariate regression analysis showed fibrillation (odds ratio [OR] = 0.95; p 0.010), LAVI < 39 mL/m2 (OR 1.23; 0.001), levels ≥ 1.73; pmol/mL 1.47; 0.001) independently predicted HFimpEF. discriminative ability better pmol/mL; alone not by combined model (irisin added NT-proBNP). Conclusions: serum natriuretic peptide patients.

Language: Английский

Citations

0
Recurrence of left ventricular systolic dysfunction and its risk factors in heart failure with improved ejection fraction patients receiving guideline-directed medical therapy: A trajectory analysis based on echocardiography DOI
Kang Fu, Zhuohao Yang, Ning Wang

et al.

International Journal of Cardiology, Journal Year: 2024, Volume and Issue: 415, P. 132370 - 132370

Published: July 17, 2024

Language: Английский

Citations

3
Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA DOI Creative Commons
Chao Chen,

Lv Jin,

Chang-Zhao Liu

et al.

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: March 8, 2024

Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in treating heart failure (HF). However, most studies have only confirmed significant impact of sGC patients with reduced left ventricular ejection fraction (LVEF). Therefore, main objective this meta-analysis was to comparatively analyze effects Vericiguat entire LVEF range based on previous studies. According PubMed, Web Science, Cochrane, and Embase databases, randomized controlled full stage were screened, two extensive clinical namely VICTORIA (LVEF&lt;45%) VITALITY-HFpEF (LVEF≥45%) identified for analysis systematic evaluation. We separately assessed rates primary outcomes, cardiovascular death, serious adverse events both The results our research that although criteria outcome not same studies, it evident there no difference between experimental group placebo (P=0.45), whereas significantly improved administration showing a improvement (RR 0.93; 95% CI 0.87 1.00), but effect mortality across 0.97; 0.86 1.09), incidence total did differ 0.96; 0.89 1.03). Surprisingly, partial subgroups found vericiguat treatment all-cause Cardiac disorders, Hypotension, Hypertension LVEF&lt;45%, particular disorders. Taken together, had benefit HF especially LVEF&lt;24%; less pronounced ≥45%, observed.

Language: Английский

Citations

1
Clinical Perspective of Myocardial Recovery and Improvement: Definitions, Prevalence, and Relevance DOI
Anthony V. Pensa, Veronica Zheng,

Lucia Davis

et al.

Methodist DeBakey Cardiovascular Journal, Journal Year: 2024, Volume and Issue: 20(4), P. 6 - 15

Published: Jan. 1, 2024

Partial or complete imaging resolution of left ventricular (LV) systolic dysfunction in patients with heart failure reduced ejection fraction (HFrEF) has gone by many names the past few decades, including LV recovery, remission, reverse remodeling, and, most recently, improvement. This phenomenon been described a variety clinical scenarios, removal an acute myocardial insult, unloading durable assist devices, and treatment various devices as well pharmacotherapies, termed guideline-directed medical therapy (GDMT). Irrespective definition, improvement is associated improved outcomes compared to persistent dysfunction. In years, distinguished from HFrEF new entity referred HF EF (HFimpEF). Given relative novelty this condition, there paucity data regard trajectory management population. review, we describe history terminology explore notable findings that have led delineation HFimpEF. Additionally, highlight importance understanding potential opportunity for GDMT clinicians when treating

Language: Английский

Citations

1
Subclinical hypothyroidism: a new risk factor for prediction of heart failure with improved ejection fraction DOI Creative Commons

Hai-Qing Zhou,

Qi Wang, Zhiquan Liu

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

Abstract BACKGROUND Heart failure (HF) with improved ejection fraction (HFimpEF) has gradually attracted widespread attention in recent years for its better clinical prognosis. In this study, we attempted to investigate the relationship between subclinical hypothyroidism (SCH) and HFimpEF. METHODS This study retrospectively collected data on patients HF reduced (HFrEF) hospitalized at First Affiliated Hospital of USTC from March 2015 September 2023, divided into two groups as euthyroidism or SCH according baseline thyroid function. Then were further categorized HFimpEF (follow-up LVEF > 40% absolute increase ≥ 10%) persistent HFrEF based their echocardiograms during follow-up period. Afterwards, logistic regression was used estimate effect RESULTS A total 916 met inclusion exclusion criteria, 396 (43.2%) progressed status Compared patients, prevalence is lower (9.3% vs. 14.4%, P = 0.020). Univariate analysis indicates that a potential risk factor (OR: 0.612 [95% CI 0.403–0.928], 0.021). After adjusting multiple factors regression, odds ratios progressing decreased by 37.8% 0.622 [95%CI 0.397–0.974], 0.038) compared euthyroidism. CONCLUSIONS demonstrated function affects improvement cardiac an independent

Language: Английский

Citations

0
Subclinical hypothyroidism: a new predictor of heart failure with improved ejection fraction in HFrEF patients DOI

Hai-Qing Zhou,

Qi Wang, Zhiquan Liu

et al.

Internal and Emergency Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

Language: Английский

Citations

0
Irisin Predicts Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide DOI Creative Commons
Tetiana A. Berezina,

Oleksandr O. Berezin,

Ye. V. Novikov

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(12), P. 1615 - 1615

Published: Dec. 17, 2024

Background: Despite existing evidence of the high predictive value natriuretic peptides (NPs) in patients with heart failure (HF), treated guideline-directed therapy who have low or near-normal NP levels are unlikely to be correctly stratified for risk clinical outcomes. The aim this study is detect plausible predictors poor one-year outcomes HFpEF and NT-proBNP accordance conventional guidelines. Methods: A total 337 HF preserved ejection fraction (HFpEF) had N-terminal pro-peptide (NT-proBNP) at discharge due optimal guideline-based were enrolled study. course observation was 3 years. Echocardiography assessment hematological biochemical parameters, including NT-proBNP, tumor necrosis factor-alpha, high-sensitivity C-reactive protein (hs-CRP), adropin, irisin, visfatin, fetuin-A, performed baseline end Results: Three-year cumulative endpoints (cardiovascular death, myocardial infarction unstable angina acute coronary syndrome, worsening HF, sudden cardiac cardiac-related surgery all-cause death) detected 104 patients, whereas 233 did not meet endpoint. After adjusting an age ≥ 64 years a presence atrial fibrillation, diabetes mellitus, chronic kidney disease (CKD) stages 1–3 dilated cardiomyopathy, multivariable Cox regression analysis showed that irisin level ≤7.2 ng/mL independent predictor Moreover, > 7.2 better Kaplan–Meier survival rate than those lower serum (≤7.2 ng/mL). Conclusions: Multivariable years; CKD cardiomyopathy; LAVI 39 mL/m2; hs-CRP 6.10 mg/L, ≤ ng/mL, visfatin 1.1 NT-proBNP. could emerge as valuable biomarker predicting long-term prognosis among

Language: Английский

Citations

0